Research programme: inflammation therapeutics - Astellas Pharma/Cengent Therapeutics
Alternative Names: IL-5 antagonists research programme - Astellas Pharma/Cengent Therapeutics; Interleukin-5 antagonists research programme - Astellas Pharma/Cengent TherapeuticsLatest Information Update: 31 Aug 2007
At a glance
- Originator Astellas Pharma; Cengent Therapeutics
- Class Small molecules
- Mechanism of Action Interleukin 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Inflammation
Most Recent Events
- 31 Aug 2007 No development reported - Preclinical for Asthma in USA (unspecified route)
- 31 Aug 2007 No development reported - Preclinical for Inflammation in Japan (unspecified route)
- 31 Aug 2007 No development reported - Preclinical for Inflammation in USA (unspecified route)